Aston Sci is a clinical-stage biopharmaceutical company dedicated to the development of innovative medicines, particularly in the fields of oncology, immunology, and geriatrics. The company is actively engaged in creating therapeutic cancer vaccines aimed at addressing unmet medical needs, especially for patients suffering from cancer recurrence, metastasis, and treatment side effects. Their pipeline includes several promising candidates, such as AST-201 for ovarian cancer and AST-301 targeting HER2-expressed gastric and breast cancers. These vaccines utilize various formulations, including peptide-based and pDNA-based vaccines, designed to elicit specific immune responses, particularly CD4+ Th1 immunity, against targeted cancer antigens.

In addition to their therapeutic cancer vaccines, Aston Sci is exploring a range of other innovative treatments, including immune adjuvants and small molecule inhibitors. Their research encompasses multiple antigen vaccines and immune checkpoint therapies, which aim to enhance the immune system's ability to fight cancer. The company is also involved in preclinical studies for various drug candidates targeting solid tumors and specific genetic mutations, demonstrating a commitment to advancing cancer treatment through cutting-edge science and technology.

South Korea

Aston Sci., a clinical stage biopharmaceutical company that is currently focusing on clinical development of innovative medicines in oncology, immunology, and geriatrics, including therapeutic cancer vaccines. Aston Sci. is constantly listening to the changing needs of the patients and will continue to move forward to improve the lives of patients who suffer from cancer recurrence, metastasis, or side effects during cancer treatment.

Cancer

Central Nervous System (CNS)

Digestive System Diseases

Urogenital Diseases

Aston Sci

Breast cancer

AST-301 (HER2 1+/2+ Breast Cancer)

Biologics

Vaccines

Gastric cancer

AST-301 (Gastric Cancer)

AST-302

Ovarian cancer

AST-201

Solid tumor/s

AST-021p

AST-023

AST-202

AST-065

Acute myeloid leukemia

AST-081

Small Molecule Pharmaceuticals

AST-05X

Central Nervous System Diseases

AST-51X

Peptide Therapies

Therapeutic

Aston Sci

Company Details